Lucid-MS, also known as Lucid-21-302, is a protein arginine deiminase 2 (PAD2) inhibitor which is under development for the treatment of multiple sclerosis. It is taken orally.
The drug is described as a non-immunomodulatory neuroprotective agent against demyelination and is said to be a potential first-in-class medication. The pharmacokinetics of Lucid-MS have been described.
It was originated by University Health Network and has been developed by FSD Pharma, Lucid Psycheceuticals, and Quantum Biopharma. As of February 2026, Lucid-MS is in phase 1 clinical trials, with at least one phase 1 trial having been completed and published. A phase 2 trial is being planned. The chemical structure of Lucid-MS does not yet appear to have been disclosed.